New Delhi: Following the approval of India’s first COVID-19 vaccine for children, the National Technical Advisory Group on Immunisation (NTAGI) will convene soon to devise a strategy for incorporating Zydus Cadila’s ZyCoV-D vaccine into the ongoing immunization drive, prioritizing those aged 12-18 years with comorbidities.
According to NTAGI Chairman Dr. N K Arora, India has around 12 crore adolescents between the ages of 12 and 18, with less than 1% having comorbidities.
“The NTAGI will meet soon to plan the introduction of the three-dose ZyCoV-D vaccine into the existing COVID-19 vaccination effort. Because this vaccination is approved for both adolescents and adults, the meeting will also prioritize beneficiaries “According to PTI, Arora said.
He went on to say, “The goal is to build a priority list with a focus on teenagers aged 12-18 years with comorbidities.” The NTAGI will develop a strategy for incorporating this vaccine into the immunization drive.
On August 20, 2021, the Drug Controller General of India approved ydus Cadila’s ZyCoV-D for Emergency Use Authorisation. The indigenously developed vaccine is being billed as the world’s first needle-free immunization based on DNA. The PharmaJet, a needle-free applicator that provides painless intradermal vaccination delivery, will be used to give it.
According to the Department of Biotechnology (DBT), when administered, ZyCoV-D, a three-dose vaccine, creates the spike protein of the SARS-CoV-2 virus and induces an immune response, which is critical for disease prevention as well as viral clearance.
It should be mentioned that preliminary data from Phase-III clinical studies including over 28,000 volunteers revealed “For symptomatic RT-PCR positive cases, the primary effectiveness was 66.6 percent. This has been India’s largest COVID-19 vaccine experiment to date “According to the DBT.